Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chubb Ltd (CB) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Chubb Limited (CB) trades at $347.83, showing minimal daily movement with a slight 0.01% gain. The stock exhibits bullish technical signals from moving averages and strong fundamental health, including consistent earnings beats and a net income margin of 18.46%. Recent news highlights disciplined capital deployment and premium growth, while the upcoming Q2 2026 earnings report on July 22, 2026, is highly anticipated.

The outlook remains positive given analyst consensus favoring Buy ratings and a price target of $354.69, suggesting modest upside. Key risks include catastrophe losses and softer commercial pricing, but the company's robust balance sheet and rising investment income support long-term growth potential for investors.